Probably, GLP-1R agonism could be a competent therapeutic strategy to combat obesity-related diabetes with minimal side effects (such as nausea and vomiting), also because of its beneficial effects on the nervous and cardiovascular systems and metabolic equilibrium (Zhao et al., 2021). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.